Biological
Abrysvo clinical trials
Also written PF-06928316.
- studies test it
- 19
- open now
- 7
- in phase 3
- 13
- first study started
- 2020
Keep track of what changes. Save the abrysvo studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- RSVpreF
- 13
Development codes
Studies by the year they started
19 studies that test it; most in 2026 (6)
| Year | Studies |
|---|---|
| 2020 | 2 |
| 2021 | 1 |
| 2023 | 3 |
| 2024 | 4 |
| 2025 | 3 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 2
- Phase 3
- 13
- Phase 4
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 4
Pfizer (14) · Tor Biering-Sørensen (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Hvivo (1) · University of British Columbia (1) · PENTA Foundation (1)
Often tested with
Tested in the same studies.
Nirsevimab (2) · Influenza Vaccines (1)
Studies
Open first, then newest update. How each study uses abrysvo is read from its arms, and is right about nine times in ten.
Testing it · 19
- A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single DoseRecruitingPhase 3PfizerNCT06866405Written as RSVpreF
- A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised AdultsRecruitingPhase 3PfizerNCT07768345Written as RSVpreF Vaccine
- A Study to Learn About the Safety and Immune Responses of RSVpreF in Older AdultsRecruitingPhase 3PfizerNCT07819097Written as RSVpreF
- Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV DiseaseNot yet recruitingPhase 3PfizerNCT07839871Written as RSVpreF
- A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreFRecruitingPhase 3PfizerNCT07653100Written as RSVpreF
- Study of HIV-Exposed Pregnancies and Transplacental Antibody Delivery Following RSVpreFNot yet recruitingPhase 4University of British ColumbiaNCT07693166Written as RSVpreF
- Pregnancy and Infant PrEparedness pLatform IN Europe, RSV-International Adaptive Platform Trial to Evaluate Two Approved Prevention Options to Prevent Respiratory Syncytial Virus in Infants: Maternal Vaccine to Women in Pregnancy and Monoclonal Antibody to the Infants, Given Alone or in Combination.Not yet recruitingPhase 3PENTA FoundationNCT07041190Written as Abrysvo
- A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.CompletedPhase 3PfizerNCT07543380Written as RSVpreF
- A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their InfantsCompletedPhase 3PfizerNCT06325657Written as RSVpreF vaccine
- Vaccine Effectiveness of a Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing RSV Hospitalizations in AdultsActive, not recruitingPhase 4Tor Biering-SørensenNCT06684743Written as RSV prefusion F protein-based vaccine
- The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both ProductsCompletedPhase 4National Institute of Allergy and Infectious Diseases (NIAID)NCT06551506Written as Abrysvo
- A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in KoreaCompletedPhase 3PfizerNCT06593587Written as RSVpreF Vaccine
- Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.Active, not recruitingPhase 3PfizerNCT05035212Written as RSVpreF
- A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in AdultsCompletedPhase 3PfizerNCT06890416Written as RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE
- A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV DiseaseCompletedPhase 3PfizerNCT05842967Written as RSVpreF
- A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.CompletedPhase 3PfizerNCT04424316Written as RSVpreF
- A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).CompletedPhase 2PfizerNCT05886777Written as RSVpreF
- A Study to Examine Respiratory Combination Vaccines Against Respiratory Syncytial Virus (RSV) and Flu in Older AdultsCompletedPhase 1PfizerNCT05788237Written as RSVpreF
- Study of RSVpreF Vaccination and RSV Challenge in Healthy AdultsCompletedPhase 2HvivoNCT04785612Written as RSVPreF
Given in every arm · 3 — abrysvo is usual care beside what is tested
- Vaccine Responses in Patients With B Cell MalignanciesRecruitingPhase 4National Heart, Lung, and Blood Institute (NHLBI)NCT05170399Written as AREXVY, ABRYSVO
- Prevention of RSV Infection in Infants by Administering Nirsevimab to Infants, With or Without Maternal RSV VaccinationRecruitingPhase 3Centre Hospitalier Annecy GenevoisNCT07232706Written as Abrysvo
- Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of AgeCompletedPhase 3PfizerNCT05301322Written as RSVpreF Vaccine
As the comparator · 1 — what is tested is compared with abrysvo
Codes
What other systems call abrysvo · ClinicalTrials.gg INT002038
- MeSH (NLM) C000729228abrysvoOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000729228 | abrysvo | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.